News & Updates

Sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) confer the greatest reduction in kidney and cardiovascular risks in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), according to a study.

The use of pembrolizumab in the neoadjuvant setting appears to be associated with a higher rate of downstaging and a survival advantage among patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy, according to a study presented at this year’s ASCO Genitourinary Cancers Symposium.

First-line treatment of advanced renal cell carcinoma (aRCC) with nivolumab plus cabozantinib (N+C) results in sustained survival and response benefits at 3 years minimum follow-up, which is consistent with previous follow-ups, according to a study presented at the 2023 ASCO GU Cancers Symposium.

Variables from the Framingham Heart Study Dementia Risk Score (FDRS) are predictive of Alzheimer’s disease (AD) and AD-related dementias (ADRD) in patients with heart failure (HF) or atrial fibrillation (AF), a study has shown.

Women with a history of infertility are more likely to develop reproductive cancers that are related to obesity, as reported in a study.